173 related articles for article (PubMed ID: 28008585)
1. Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro.
Li XN; Bu HM; Ma XH; Lu S; Zhao S; Cui YL; Sun J
Exp Clin Endocrinol Diabetes; 2017 Feb; 125(2):91-97. PubMed ID: 28008585
[No Abstract] [Full Text] [Related]
2. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Eftekhari S; Montazeri H; Tarighi P
Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
[TBL] [Abstract][Full Text] [Related]
3. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.
Li Y; Tweedie D; Mattson MP; Holloway HW; Greig NH
J Neurochem; 2010 Jun; 113(6):1621-31. PubMed ID: 20374430
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 analogs activate AMP kinase leading to reversal of the Warburg metabolic switch in breast cancer cells.
Ligumsky H; Amir S; Arbel Rubinstein T; Guion K; Scherf T; Karasik A; Wolf I; Rubinek T
Med Oncol; 2024 May; 41(6):138. PubMed ID: 38705935
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.
Koehler JA; Kain T; Drucker DJ
Endocrinology; 2011 Sep; 152(9):3362-72. PubMed ID: 21771884
[TBL] [Abstract][Full Text] [Related]
7. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.
Shi L; Ji Y; Jiang X; Zhou L; Xu Y; Li Y; Jiang W; Meng P; Liu X
Cardiovasc Diabetol; 2015 Feb; 14():18. PubMed ID: 25855361
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving β-catenin.
Wu X; Li S; Xue P; Li Y
Exp Cell Res; 2017 Nov; 360(2):281-291. PubMed ID: 28919123
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T; Kawanami T; Irie S; Hamaguchi Y; Terawaki Y; Murase K; Tsutsumi Y; Nagaishi R; Tanabe M; Morinaga H; Tanaka T; Mizoguchi M; Nabeshima K; Tanaka M; Yanase T
Diabetes; 2014 Nov; 63(11):3891-905. PubMed ID: 24879833
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice.
Li Y; Bader M; Tamargo I; Rubovitch V; Tweedie D; Pick CG; Greig NH
J Neurochem; 2015 Dec; 135(6):1203-1217. PubMed ID: 25982185
[TBL] [Abstract][Full Text] [Related]
13. Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway.
Zhang X; Bi L; Ye Y; Chen J
Nutr Cancer; 2014; 66(4):656-61. PubMed ID: 24666255
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
Mhaidat NM; Zhang XD; Jiang CC; Hersey P
Clin Cancer Res; 2007 Feb; 13(4):1308-14. PubMed ID: 17317842
[TBL] [Abstract][Full Text] [Related]
15. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
16. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress.
Sharma MK; Jalewa J; Hölscher C
J Neurochem; 2014 Feb; 128(3):459-71. PubMed ID: 24112036
[TBL] [Abstract][Full Text] [Related]
18. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation.
Ye Y; Hou R; Chen J; Mo L; Zhang J; Huang Y; Mo Z
Horm Metab Res; 2012 Apr; 44(4):263-7. PubMed ID: 22328166
[TBL] [Abstract][Full Text] [Related]
19. The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism.
Andreozzi F; Raciti GA; Nigro C; Mannino GC; Procopio T; Davalli AM; Beguinot F; Sesti G; Miele C; Folli F
J Transl Med; 2016 Jul; 14(1):229. PubMed ID: 27473212
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 analogues exenatide and liraglutide exert inhibitory effect on the early phase of liver regeneration after partial hepatectomy in rats.
Fontana J; Kučera O; Mezera V; Anděl M; Červinková Z
Physiol Res; 2017 Nov; 66(5):833-844. PubMed ID: 28730824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]